Phrontline Biopharma Suzhou closed a $60 million pre‑A+ financing round led by Lapam Investment to support development of next‑generation bispecific antibody‑drug conjugates (ADCs) and dual‑linker payload technologies. The round included strategic and financial investors and will fund GLP toxicology, manufacturing scale‑up and additional preclinical programs. Phrontline’s platform combines bispecific antibody scaffolds with novel payload linkers designed for improved tumor selectivity and potency; management cited regulatory and commercial timelines in China and global expansion as priorities for the new capital. The financing reflects sustained investor interest in ADC modalities and the competitive race to deliver improved safety and efficacy profiles for ADCs across multiple solid tumor indications.